Hikal Limited Stock Price Today (NSE: HIKAL)
Fundamental Score
Hikal Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Hikal Limited share price today is ₹224.38, up +5.73% on NSE/BSE as of 16 September 2026. Hikal Limited (HIKAL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.77K (Cr). The 52-week high for HIKAL share price is ₹282.70 and the 52-week low is ₹146.25. The company has a Return on Equity (ROE) of -3.97% and a debt-to-equity ratio of 0.57.
Hikal Limited Share Price Chart — NSE/BSE Historical Performance
Hikal Limited share price chart: 7.11% return over the past month. 52-week high ₹282.70, 52-week low ₹146.25.
Hikal Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹211.87 | ₹226.00 | ₹203.83 | ₹224.38 | 18.18L (Cr) | |
| ₹227.87 | ₹227.87 | ₹210.15 | ₹212.22 | 8.52L (Cr) | |
| ₹231.02 | ₹232.39 | ₹221.98 | ₹224.95 | 9.03L (Cr) | |
| ₹241.50 | ₹245.00 | ₹233.10 | ₹234.78 | 7.74L (Cr) | |
| ₹245.88 | ₹245.90 | ₹238.76 | ₹240.69 | 12.71L (Cr) | |
| ₹246.20 | ₹253.80 | ₹238.19 | ₹246.01 | 65.61L (Cr) | |
| ₹222.01 | ₹257.00 | ₹218.82 | ₹243.00 | 310.89L (Cr) | |
| ₹234.00 | ₹236.74 | ₹220.10 | ₹222.30 | 53.59L (Cr) | |
| ₹201.15 | ₹240.72 | ₹201.15 | ₹240.36 | 201.96L (Cr) | |
| ₹198.88 | ₹202.99 | ₹197.01 | ₹200.60 | 2.38L (Cr) |
Hikal Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹201.00 | ₹257.00 | ₹197.01 | ₹224.38 | +11.63% | |
| ₹222.20 | ₹239.90 | ₹195.00 | ₹201.41 | -9.36% | |
| ₹221.88 | ₹252.80 | ₹208.00 | ₹221.31 | -0.26% | |
| ₹193.91 | ₹225.80 | ₹174.97 | ₹221.38 | +14.17% | |
| ₹189.25 | ₹228.00 | ₹189.25 | ₹195.28 | +3.19% | |
| ₹155.00 | ₹194.79 | ₹150.22 | ₹189.25 | +22.10% | |
| ₹187.00 | ₹195.00 | ₹146.25 | ₹147.08 | -21.35% | |
| ₹190.10 | ₹222.80 | ₹177.35 | ₹196.68 | +3.46% | |
| ₹227.79 | ₹229.10 | ₹188.80 | ₹192.58 | -15.46% | |
| ₹224.87 | ₹261.00 | ₹222.28 | ₹226.83 | +0.87% | |
| ₹239.00 | ₹247.00 | ₹218.00 | ₹222.92 | -6.73% | |
| ₹252.00 | ₹257.50 | ₹236.20 | ₹238.35 | -5.42% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Hikal Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Hikal Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of HIKAL across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (15.23%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (22.51%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Cash Generation (₹312.61 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (68.85%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (-3.97%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.95%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Limited Growth History (-0.09% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-22.89% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-22.89% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-0.26x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 8.64%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Hikal Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Hikal Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Hikal LimitedHikal Limited...Selected✓ HIKAL • 524735 | 24.6/100 | ₹224.38₹224 | ₹2771.09₹2771.09 | — — | -3.97%Poor -3.97% Poor | -0.95%Poor -0.95% Poor | 0.57Good 0.6 Good | -22.89%Poor -22.89% Poor | -0.09%Poor -0.09% Poor | 0.58% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Hikal Limited PE Ratio History
Historical price-to-earnings ratio for HIKAL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹7.36 | ₹226.83 | 30.8x |
| FY 2024 | ₹5.64 | ₹390.50 | 69.2x |
| FY 2023 | ₹6.36 | ₹303.95 | 47.8x |
| FY 2022 | ₹13.02 | ₹410.10 | 31.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Hikal Limited Dividend History
Annual cash dividends paid by HIKAL — dividend yield 0.58%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹14.80 Cr |
| FY 2024 | ₹14.80 Cr |
| FY 2023 | ₹12.33 Cr |
| FY 2022 | ₹27.13 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Hikal Limited Quarterly Performance
Latest quarterly metrics for HIKAL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
5.89%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
22.51%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-0.09%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-22.89%
Compounded annual net profit growth over 5 years
Hikal Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for HIKAL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Hikal Limited Financial Statements
Annual income statement, balance sheet and cash flow for Hikal Limited (HIKAL) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Hikal Limited
About HIKAL (Hikal Limited)
Hikal Ltd is a dynamic and innovative pharmaceutical company carving a distinct niche within the global healthcare landscape. Focusing on the intricate synthesis and production of ...specialized chemical compounds, Hikal caters to a diverse spectrum of industries, ranging from pharmaceutical giants developing life-saving medications to pioneering biotechnology firms exploring novel therapies. The company's expertise lies in its ability to meticulously craft chemical intermediates, which serve as the vital building blocks for more complex pharmaceutical formulations and specialty chemicals. Hikal is known for its agility and commitment to delivering high-quality products that meet the stringent requirements of regulated markets, bolstering its reputation as a trusted partner for companies seeking reliable and innovative solutions. Strategically structured into two key operational pillars – Pharmaceuticals and Crop Protection – Hikal optimizes its resources and expertise to address distinct market demands. The Pharmaceutical segment is the core of the company, focusing on research, development, and manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates. This segment has a wide portfolio of products that are sold to regulated markets across the globe. The Crop Protection segment is a strong growth pillar that manufactures herbicides and pesticides and has seen strong demand. The company is committed to developing sustainable and environmentally friendly products. Hikal leverages its profound understanding of chemical processes and regulatory frameworks to offer a comprehensive suite of services that span the entire product lifecycle. This integrated approach, combined with its state-of-the-art manufacturing facilities and a dedicated team of skilled scientists and engineers, enables Hikal to consistently deliver innovative and customized solutions to its clients. By prioritizing quality, efficiency, and sustainability in all its operations, Hikal is solidifying its position as a valuable partner within the global pharmaceutical and crop protection industries, contributing to the advancement of healthcare and agriculture worldwide.
Company Details
Key Leadership
HIKAL Share Price: Frequently Asked Questions
What is the current share price of Hikal Limited?
Hikal Limited (HIKAL) trades at ₹224.38 on NSE and BSE. Market cap ₹2.77K (Cr). Educational data only.
What is the P/E ratio of Hikal Limited?
Hikal Limited has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Hikal Limited?
Hikal Limited has a Bull Run score of 24.6/100 based on 25+ financial parameters.
Does Hikal Limited pay dividends?
Hikal Limited has a dividend yield of 0.58%. Past dividends don't guarantee future payments.
What is the ROE of Hikal Limited?
Hikal Limited has ROE of -3.97%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Hikal Limited?
Hikal Limited has debt-to-equity of 0.57.
Is Hikal Limited a good investment?
Bull Run gives Hikal Limited a score of 24.6/100. This is not investment advice — consult a SEBI-registered advisor.